Page 177 - Presents News Today

Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen's differentiated PARP inhibitor RP12146, indicates

Pass the Hat presents One Man Band, Andy Twyman in The Queen Charlotte Rochester, Sat 9th April Hosted By Music Management & Promotions - Europe. Event starts on Saturday, 9 April 2022 and happening at Queen Charlotte, Rochester, EN. Register or Buy Tickets, Price information.

Kinepolis Group publishes annual integrated report 2021 Regulatory release 8 April 2022, 8 a.m. Kinepolis Group presents its annual integrated report 2021, which provides a... | April 8, 2022

SAN FRANCISCO, April 08, 2022. "This is an eventful year for T-knife, filled with meaningful corporate milestones," stated Thomas M. Soloway, Chief Executive Officer of T-knife. "Today's announcement

Unique Structure and Tetravalency of FS118 Is Required to Modulate LAG-3 Cell Surface ExpressionCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 08, 2022(NASDAQ: FSTX), a clinical-stage biopharmaceutical

Novel, investigational drug JZP815 inhibited tumor growth in several RAS- and BRAF-mutated solid tumor models, and demonstrated enhanced activity when combined with other MAPK pathway inhibitors Jazz

TET platform shows efficient T cell priming and beneficial safety profile Data supported clinical transition to ongoing TENDU Phase I trialTET platform offers potential to strengthen T cell response to

- MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung cancer (NSCLC) cells- MCLA-129 significantly inhibits

- Pelareorep's immunotherapeutic effects produced progression-free survival of >3 years in a subset of multiple myeloma patients who had failed prior therapy - Results strengthen the clinical

OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the presentation of preclinical proof-of-concept data on its lead candidate